BioCardia (BCDA) Income towards Parent Company (2010 - 2026)
BioCardia's (BCDA) quarterly Income towards Parent Company came in at -$1.6 million in Q2 2026, up 20.87% year-over-year from -$1.3 million in Q2 2025, and up 28.38% quarter-over-quarter from -$2.3 million in Q1 2026.
Analysis
BioCardia (BCDA) Income towards Parent Company (2010 - 2026) Analysis & Trends
BioCardia (BCDA) has reported Income towards Parent Company for 15 consecutive years, with -$1.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Income towards Parent Company rose 20.87% year-over-year to -$1.6 million in Q2 2026; TTM through Jun 2026 was -$7.4 million, a 26.85% increase from a year earlier, with the FY2025 full-year figure at -$1.4 million, down 7.69% from the prior year.
- Income towards Parent Company was -$1.6 million for Q2 2026 at BioCardia, up from -$2.3 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$1.5 million in Q3 2025 and troughed at -$3.6 million in Q4 2024.
- A 5-year average of -$2.5 million and a median of -$2.5 million in 2022 frame the typical range for Income towards Parent Company.
- The widest YoY moves for Income towards Parent Company: up 52.23% in 2024, down 73.75% in 2024.
- Over 5 years, Income towards Parent Company stood at -$3.0 million in 2022, then soared by 30.95% to -$2.1 million in 2023, then sank by 73.75% to -$3.6 million in 2024, then soared by 58.91% to -$1.5 million in 2025, then decreased by 9.07% to -$1.6 million in 2026.
- The last three Income towards Parent Company figures came in at -$1.6 million (Q2 2026), -$2.3 million (Q1 2026), and -$1.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.62 Mn |
| Mar 31, 2026 | -2.27 Mn |
| Sep 30, 2025 | -1.49 Mn |
| Jun 30, 2025 | -2.05 Mn |
| Mar 31, 2025 | -2.73 Mn |
| Dec 31, 2024 | -3.62 Mn |
| Sep 30, 2024 | -1.76 Mn |
| Jun 30, 2024 | -1.65 Mn |
| Mar 31, 2024 | -2.28 Mn |
| Dec 31, 2023 | -2.08 Mn |
| Sep 30, 2023 | -2.60 Mn |
| Jun 30, 2023 | -3.45 Mn |
| Mar 31, 2023 | -3.51 Mn |
| Dec 31, 2022 | -3.02 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | -2.50 Mn |
| Mar 31, 2022 | -3.33 Mn |
| Dec 31, 2021 | -3.46 Mn |
| Sep 30, 2021 | -2.71 Mn |
| Jun 30, 2021 | -3.49 Mn |